Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Treasury Shares (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Treasury Shares for 12 consecutive years, with $7.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 33.96% to $7.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.1 million, a 33.96% increase, with the full-year FY2025 number at $7.1 million, up 33.96% from a year prior.
  • Treasury Shares was $7.1 million for Q4 2025 at Myriad Genetics, down from $7.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $7.6 million in Q2 2025 to a low of $3.1 million in Q4 2021.
  • A 5-year average of $4.9 million and a median of $4.7 million in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: skyrocketed 78.95% in 2021, then decreased 8.93% in 2025.
  • Myriad Genetics' Treasury Shares stood at $3.1 million in 2021, then rose by 19.35% to $3.7 million in 2022, then increased by 18.92% to $4.4 million in 2023, then grew by 20.45% to $5.3 million in 2024, then soared by 33.96% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Treasury Shares are $7.1 million (Q4 2025), $7.5 million (Q3 2025), and $7.6 million (Q2 2025).